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Abstract
Background: HIV, HBVand HCV is major public health concerns. Because of shared routes of
transmission, HIV-HCV coinfection and HIV-HBV coinfection are common. HIV-positive individuals
are at risk of coinfection with HBV and HCV infections. The prevalence rates of coinfection with
HBV and HCV in HIV-patients have been variable worldwide depending on the geographic regions,
and the type of exposure.
Aim: This study aimed to examine HBV and HCV coinfection serologically and determine the
shared and significant factors in the coinfection of HIV-positive patients.
Methods: This descriptive, cross-sectional study was carried out on 391 HIV-positive patients
including 358 males and 33 females in Lorestan province, west Iran, to survey coinfection with
HBsAg and anti-HCV. The retrospective demographic data of the subjects was collected and the
patients' serums were analyzed by ELISA kits including HBsAg and anti-HCV. The collected data
was analyzed with SPSS software (15) and Chi-square. Fisher's exact test with 5% error intervals
was used to measure the correlation of variables and infection rates.
Results: The results of the study indicated that the prevalence of coinfection in HIV-positive
patients with hepatitis viruses was 94.4% (370 in 391), out of whom 57 (14.5%) cases were HBsAg
positive, 282 (72%) cases were anti-HCV positive, and 31 (7.9%) cases were both HBsAg and anti-
HCV positive.
Conclusion: There was a significant correlation between coinfection with HCV and HBV and/or
both among HIV-positive patients depending on different variables including sex, age, occupation,
marital status, exposure to risk factors.(p < 0.001).
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Background
Human immunodeficiency virus (HIV), hepatitis B virus
(HBV), and hepatitis C virus (HCV) are major public
health concerns. Because of shared routes of transmission,
HIV-HCV coinfection and HIV-HBV coinfection and/or
both are common [1,2]. HIV-positive individuals are at
risk of coinfection with HBV and HCV and/or both infec-
tions [3]. Coinfections of HBV and HCV with HIV have
been associated with reduced survival, with an increased
risk of progression to severe liver diseases and an
increased risk of hepatotoxicity associated with antiretro-
viral therapy [1]. Worldwide, HIV is responsible for 38.6
million infections as estimated at the end of 2005 while
HBV and HCV account for around 400 million and 170
million chronic infections, respectively. Moreover, among
the HIV infected patients, 2-4 million are estimated to
have chronic HBV coinfection while 4-5 million are coin-
fected with HCV [4]. An estimated one-third of the deaths
in HIV patients are directly or indirectly related to liver
diseases [5]. The prevalence rates of coinfection with HBV
and HCV in HIV patients have been variable worldwide
depending on the geographic regions, risk groups and the
type of exposure involved which may be different not only
from country to country, but also in different regions of
the same country [6-8]. This study aimed to examine HBV
and HCV coinfection in HIV-positive patients in Lorestan
province, west Iran, serologically in order to recognize the
prevalence rates of coinfection with these viruses in HIV-
positive patients and the involving factors so that the
results could increase clinical information in order to
assess and treat the infections.
Methods
This study aimed to examine HBV and HCV coinfection in
HIV-positive patients in Lorestan province in Iran serolog-
ically in order to recognize the prevalence rates of coinfec-
tion with these viruses in HIV-positive patients and the
involving factors so that the results could increase clinical
information in order to assess and treat the infections.
Study population
This descriptive, cross-sectional study from January 2007
to January 2008 was carried out on 391 HIV-positive
patients including 358 males and 33 females in Lorestan
province which is located in west Iran.
Sampling
In this study, the serum samples from confirmed HIV-pos-
itive patients were measured by commercially available
Enzyme Linked Immunosorbent Assay (ELISA) kits for the
presence of HBsAg (Dialups, USA) and anti-HCV antibod-
ies (Dialups USA, 3rd generation).
Statistical analysis
The retrospective demographic data of the subjects was
collected and then the data was analyzed using the SPSS
software -15.0 version - and Chi-square and Fisher's exact
test with 5% level of significance was used to measure the
association between the variables and infection rates.
Results
The retrospective demographic data of the subjects
showed that out of the 391 HIV-positive patients, 358
(91.6%) and 33 (8.4%) were males and females, respec-
tively. Overall, the prevalence rates of coinfection of
HBsAg and anti-HCV antibodies and both HBsAg and
anti-HCV in HIV-positive patients were 282 (72%), 57
(14.5%) and 31(7.9%), respectively. (Table 1) The rate of
the total HBsAg coinfection was 14.5% (57 in 391) in
HIV-positive patients. Among the males, HIV/HBV coin-
fection was seen in 40 (11.2%) out of the 391 patients
while among the females, HIV/HBV coinfection was
observed in 17 (4.3%) out of the 391 patients. The rate of
the total HCV coinfection was 72% (282 in 391) in HIV-
positive patients. Among the males, HIV/HCV coinfection
was seen in 274 (70%) out of the 391 patients while
among the females, HIV/HCV coinfection was found in 8
(2%) out of the 391 patients. The rate of both HBV/HCV
coinfections was 7.9% (31 in 391) in HIV-positive
patients. Among the male HIV-positive patients, HBV/
HCV coinfections were seen in 24 (6.1%) out of 391 while
among the female HIV-positive patients, HBV/HCV coin-
fections were found in 7 (1.7%) out of 391. In addition,
the following results from chi-square tests were obtained
by investigating various variables including age, sex, occu-
pation, marital status, and exposure to risk factors in HIV-
positive patients:
Age
There was a significant relationship between age and con-
dition of infection with HBV and HCV in HIV-positive
patients (p = 0.0013) so that the infection rate with only
HCV in HIV-positive patients under 40 was clearly more
than those in other age groups (77.2% in patients under
30 and 74.2% in patients between 31-50), but for HIV it
was less than the rates in other age groups (12.9% in
patients under 30 and 13.2% in 31-50 age range), and
finally HBV/HCV coinfections rate in the age groups of
HIV-positive patients under 40 and above 60 was less than
the rates in other groups (5.7% in patients under 30, and
8.9% in the patients of 31-50).
Sex
Regarding gender, there was a significant relationship (p <
0.001), namely the infection with only HCV in HIV-posi-
tive men was more than the infection in HIV-positive
women (69% and 24.3%, respectively) and the infection
with HBV in HIV-positive female patients was more thanVirology Journal 2009, 6:202 http://www.virologyj.com/content/6/1/202
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that in HIV-positive male patients (51.5% vs. 11.2%), and
finally HBV/HCV coinfections in HIV-positive women
exceeded that for HIV-positive male patients (21.2% and
6.7%, respectively).
Occupation
A significant relationship was found between occupation
of HBV/HCV coinfections of HIV-positive patients (p <
0.001) so that the most infection with only HCV was in
unemployed patients (78.7%) while farmers and ranchers
(100%) and housewives (50%) suffered from the most
infection with only HBV, and the most HBV/HCV coinfec-
tion was for housewives (21.9%).
Marital status
Marital status was found to be a significant factor (p <
0.001) so that the infection with only HCV in single HIV-
positive patients was more than that in married HIV-pos-
itive patients (82% and 59.7%, respectively). Moreover,
the infection with only HBV in married HIV-positive
patients was more than that in single HIV-positive
patients (24% vs. 7.2%), and HBV/HCV coinfections rate
in married HIV-positive patients was more than that for
single HIV-positive patients (10.6% vs. 5.7%).
Risk factors
A significant relationship was found between type of
exposure to risk factors and condition of infection of HCV
and HBV (p < 0.001), namely the rates of infection with
only HCV in patients with blood transfusion and addic-
tion to drug injection history being 100% and 85.2%,
respectively were precisely more than those for other risk
factors while the infection rate with only HBV in preg-
nancy (40%) and in having infected family member(s)
(31.5%) was more than those for other factors. Moreover,
and HBV/HCV coinfections rates in patients with suspi-
Table 1: Prevalence rate of HBV & HCV positivity among HIV+ patient
HBsAg+ Anti-HCV+ Double Positive
Variable N (Percent) N P N P N P
Total 391(100%) 57(14.5%) 282 (72%) 31 (7.9%)
Sex <0.001 <0.001 <0.001
Male 358 (91.6%) 40(11.2%) 274(76.5%) 24 (6.7%)
Female 33 (8.4%) 17(51.5%) 8 (24.3%) 7 (21.2%)
Age 0.013 <0.001 <0.001
≤ 30 140 (35.8%) 18(12.9%) 108 (77.2%) 8 (5.7%)
31-50 204 (52.1%) 27(13.2%) 151 (74%) 18 (8.9%)
≥ 50 47 (12%) 12(25.5%) 23 (48.9%) 5 (10.6%)
Marital status <0.001 <0.001 <0.001
Single 195 (49.8%) 14(7.2%) 160 (82%) 11(5.7%)
Married 166 (42.4%) 40(24%) 99 (59.7%) 18 (10.6%)
Other 30 (7.6%) 3 (10%) 23 (76.7%) 2 (6.7%)
Risk Factor <0.001 <0.001 <0.001
IDU 202 (51.6%) 12 (5.9%) 172 (85.2%) 8 (3.1%)
Sexual 11 (2.8%) 4 (3.4%) 3 (27.3%) 1 (9%)
Transfusion 12 (3%) 0 (0%) 12 (100%) 0 (0%)
Sex & IDU 56 (14.3%) 6 (10.7%) 36 (64.3%) 13(23.2%)
Pregnant 5 (1.2%) 2 (40%) 0 (0%) 0 (0%)
Other 105 (26.8%) 33(31.5%) 59 (56.2%) 9 (8.6%)
Occupation <0.001 <0.001 <0.001
Unemployed 221 (56.5%) 16 (7.2%) 174 (78.7%) 15 (6.8%)
Self employed 63 (16.1%) 8 (12.7%) 47 (74.6%) 4 (6.3%)
Worker 42)10.7%) 6 (14.3%) 33 (78.6%) 3 (7.2%)
Employee 3 (0.7%) 1) 33.3%) 2 (66.7%) 0) 0%)
housewife 32 (8.1%) 16 (50%) 8) 25%) 7 (21.9%)
Farmer 4 (1%) 4 (100%) 0 (0%) 0 (0%)
Student 12 (3%) 3 (25%) 9 (75%) 0 (0%)
Driver 10 (2.5%) 2 (20%) 6 (60%) 20 (20%)
Other 4 (1%) 1 (25%) 3 (75%) 0 (0%)
HBsAg: HBV surface antigen, anti-HCV: antibody against HCV, N: number of patients, p: p-value, IDU: Injection drugs usersVirology Journal 2009, 6:202 http://www.virologyj.com/content/6/1/202
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cious sexual relationships and addiction to drug injection
(Sex & IDU) were more than those for other risk factors
(23.2%).
Discussion
The primary purpose of the present study was to estimate
the prevalence rate of HBV/HCV co-infection in HIV-pos-
itive patients in Lorestan province in Iran. Therefore, the
study considered the common belief that most of HBV/
HCV coinfections in HIV-positive patients are due to the
shared routes of transmission of the viruses. So, the study
showed some similarities and differences in the preva-
lence rates of HBV/HCV co-infection in HIV-positive
patients in comparison to the studies carried out in our
country, Iran, and in other developing and developed
countries. They could be attributed to the epidemiologic
conditions of the viruses that depend on various factors
including the overlapping degree of risk factors in order to
get infected with these viruses. In the US and Europe, HIV/
HBV co-infection was reported to be 6 to 14% while
reports for HIV/HCV varied in the range of 25 to 50%
[9,10]. In a similar study carried out in Ahvaz - South Iran,
the co-infection rates of HBV, HCV, and HBV/HCV in
HIV-positive patients were found to be 44, 74, and 20%,
respectively [11], and in our study the rates were 14.5%
for HIV-HBV, 72% for HIV-HCV, and 7.9% for HBV/HCV
coinfections. In another study performed on 150 HIV-
positive patients in a private clinic in Tehran - the capital
of Iran, HBV and HCV coinfection rates were 9.4 and
68%, respectively [12]. The results of a study in Nigeria
conducted on 1779 HIV-positive patients revealed that
the rates for HBsAg, HCV, and HBV/HCV coinfections
were 11.9, 4.8, and 1%, respectively [13]. Moreover, in
India, a study showed that the prevalence rate of HBsAg in
HIV-positive patients was 3.4% while the rate for HCV-Ab
was reported to be 0% [14]. Or in a similar study in north-
ern India on 620 HIV-positive patients, the rate for HBV
was 2.25%, for HCV 1.6%, and for both HBV/HCV coin-
fections it was less than 1% [15]. In Brazil the results of a
study showed the rates of 6.4 and 5% for HBsAb and
HCV-Ab coinfection in HIV-positive patients [16]. Also
various reports of the prevalence rates of these viruses in
HIV-positive patients exist [17-19]. The higher prevalence
rate of HCV in HIV-positive patients in comparison to the
rate for HBV in HIV-positive patients could be considered
as noticeable and it could be attributed to diverse factors
particularly lack of vaccines for HCV contrary to the exist-
ence of vaccines for HBV. Also, sexual transmission of this
virus is lower in comparison to HBV and it is transmitted
mostly via injection (especially in drug addiction) mostly
because of the increasing rate of addiction in Iran [20]. In
a study in Tabriz -west Iran, that investigated HIV/HBV/
HCV co-infections in pregnant women, the prevalence
rates of HBsAg, HCV-Ab, and HIV on 680 blood samples
were 2.5, 1, and 0%, respectively [21]. Or in another study
investigating the three viruses of HIV, HBV, and HCV on
2167 blood samples taken from blood donors, the rates
for HBV, HCV, and HIV were 4.6%, 2.9%, and 0. 6%,
respectively [22]. Many studies have been conducted in
this realm [23], all showing high rates for the viruses in
HIV-positive patients due to the above-mentioned factors.
Some patients are currently infected with the three viruses
of HIV, HBV, and HCV due to their shared risk factors.
Consequently, coinfection with the three viruses will
increase the risk of cirrhosis, liver deficiency, and mortal-
ities in comparison to when a person is infected with only
one of these viruses. Therefore, diagnosing HBV and HCV
in HIV-positive patients is vital in order to take care of
them and allot resources in health plans so that all HIV-
positive patients have to be tested for both HVB and HCV
[24,25].
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